Biotechnology

Innovent Biologics Announces Positive Updated Result from the Incyte-sponsored Phase II Trial of Pemigatinib in Patients with Previously Treated, Advanced Cholangiocarcinoma

SUZHOU, China, Oct. 21, 2019 /PRNewswire/ --  Innovent Biologics, Inc. ("Innovent" or "the Company") (HKEX: 01801), a world-class biopharmaceutical company that develops and commercializes high quality medicines for the treatment of oncology, autoimmune, metabolic and other major diseases, today ...

2019-10-21 08:00 245

China Biologic Special Committee Retains Financial Advisor and Legal Counsel

BEIJING, Oct. 17, 2019 /PRNewswire/ -- China Biologic Products Holdings, Inc. (NASDAQ: CBPO, "China Biologic" or the "Company"), a leading fully integrated plasma-based biopharmaceutical company inChina, today announced that the special committee (the "Special Committee") of the Company's board o...

2019-10-17 20:00 3103

GELITA & Geltor Sign Letter of Intent to Commercialize First Animal-Free Biodesigned Collagen for Dietary Supplements, a Market with Huge Growth Potential

LAS VEGAS, Oct. 17, 2019 /PRNewswire/ -- In the halls of the SupplySide West (SSW) Expo, officials from both GELITA and Geltor signed a letter of intent for developing, producing and marketing the first ingestible animal-free collagen proteins – to be launched in late 2020. In this arrangement, G...

2019-10-17 18:32 366

MetGen Earns Acclaim from Frost & Sullivan for its Unique, Customized Enzyme Technologies, METNIN™ and ENZINE®

The technologies solve the industry's major pain points regarding the valorization of lignin, shorter technology development cycles, and customization of enzymes for different applications LONDON, Oct. 17, 2019 /PRNewswire/ -- Based on its recent analysis of the European industrial enzymes marke...

2019-10-17 15:00 312

Sirtex Medical appoints Kevin R. Smith as Chief Executive Officer

Interim CEO unanimously chosen to lead global operations in patient-first oncology innovation WOBURN, Mass., Oct. 16, 2019 /PRNewswire/ -- Sirtex Medical, a leading manufacturer of targeted liver cancer therapies, today announced the appointment ofKevin R. Smith as Chief Executive Officer of Sir...

2019-10-16 22:00 595

The 26th China Yangling Agricultural High-tech Achievements Expo will begin on October 22

YANGLING, China, Oct. 16, 2019 /PRNewswire/ -- On October 15, over ten international reporters, representing, among others, the European Pressphoto Agency, the Colpisa News Agency, the Korean Central News Agency, Radio-Television Slovenia, and the Republic of Korea's "Asian Economy", visited Yan...

2019-10-16 19:28 226

Curiox Biosystems Achieves Commercialisation and Fund Raising Success in North Asia with the Support of Cornerstone Investor, ZIG Ventures

* CURIOX BIOSYSTEMS, is an A*STAR spinoff company, that develops bioinstrumentation solutions used in cell analysis and therapy for the pharmaceutical and biotech industries. The company has successfully penetrated theUSA, PRC, Korean and European markets and also secured a Series B funding of ...

2019-10-16 07:00 355

Celemics Expedites Target Enrichment NGS Data Insights by Partnering With BlueBee on a Global Genomics Data Solution

SEOUL, South Korea, and RIJSWIJK, The Netherlands, Oct. 15, 2019 /PRNewswire/ -- Celemics, provider of NGS target enrichment kits and innovative sequencing platforms, announced today the release of a comprehensive NGS target enrichment workflow for clinical and translational research applications...

2019-10-15 19:00 321

WuXi AppTec Research Service Division and BioSolveIT Introduce GalaXi®, a Vast New Chemical Space of Tangible Molecules

SHANGHAI and CAMBRIDGE, Massachusetts and SANKT AUGUSTIN, Germany, Oct. 10, 2019 /PRNewswire/ -- WuXi AppTec Research Service Division and BioSolveIT today launched a new virtual chemical space called GalaXi®. Largely built from WuXi AppTec's library of novel drug-like scaffolds, GalaXi® offers a...

2019-10-11 08:02 5934

CTFH and Insilico Medicine Enter Al Drug Discovery Collaboration Focused On Accelerating First-in-Class Therapeutics, Worth Up to $200 million

HONG KONG and NANJING, China, Oct. 9, 2019 /PRNewswire/ -- Insilico Medicine, a company developing an end-to-end drug discovery pipeline utilizing the latest advances in deep learning, has entered into a two-program AI drug discovery collaboration agreement with Jiangsu Chia Tai Fenghai Pharmaceu...

2019-10-09 20:58 470

Datar Cancer Genetics Announces Positive Results With 42.9% Objective Response Rate, and 90.5% Disease Control Rate in Heavily Pre-treated Patients With Ultra-personalised Pan-cancer Treatment Protocol in the RESILIENT Trial

LONDON, MUMBAI, India and BAYREUTH, Germany, Oct. 9, 2019 /PRNewswire/ -- - RESILIENT Protocol captures Encyclopedic information from tumors and uses Artificial Intelligence (AI) to optimize treatments; - Objective Response and Disease Control Comparable to or better than most Immunotherapy opti...

2019-10-09 17:56 762

Ascletis Appoints Former Novartis Global Head Dr. Handan He as Chief Scientific Officer

HANGZHOU, China and SHAOXING, China, Oct. 8, 2019 /PRNewswire/ -- Ascletis Pharma Inc. (1672.HK), an innovative R&D driven, commercial-stage biotechnology company addressing unmet medical needs in therapeutic areas including anti-viral, cancer and fatty liver diseases, announces today that Dr.Han...

2019-10-08 08:00 452

Cross-industrial technologies make a splash in Asia Agri-Tech Expo in Taipei

TAIPEI, Oct. 5, 2019 /PRNewswire/ -- The Asia Agri-Tech Expo & Forum 2019 will take place at Taipei Nangang Exhibition Center Hall 1 fromOctober 31 to November 2. Organised by Informa Markets of Taiwan Office (UBM Taiwan), the tradeshow features innovative, eco-friendly and sustainable manufac...

2019-10-05 10:06 219

Medicago's New Drug Submission accepted for scientific review by Health Canada: An important step for Medicago towards commercialization of its innovative influenza vaccine

QUEBEC CITY, Oct. 3, 2019 /PRNewswire/ -- Medicago, a biotechnology company and global leader in the development and production of plant-derived vaccines with headquarters inQuebec City, announces today that Health Canada accepted for scientific review its New Drug Submission (NDS) for a plant-ba...

2019-10-03 06:30 386

AGC Biologics Appoints New Site Head/General Manager of Copenhagen, Denmark Operations

Jeffrey D. Mowery Named Site Head/General Manager BOTHELL, Washington, Oct. 1, 2019 /PRNewswire/ -- AGC Biologics, a global leader in clinical and commercial manufacturing of therapeutic proteins, announced today the appointment ofJeffery D. Mowery as Site Head/General Manager of theCopenhagen,...

2019-10-01 07:00 368

Interleukin 11 Identified as New Therapeutic Target for Idiopathic Pulmonary Fibrosis

* Idiopathic pulmonary fibrosis (IPF) is a severe and fatal disease that causes lung damage and scarring * Blocking a protein called interleukin-11 (IL11), which is abnormally high in the lungs of patients with IPF, can reverse lung fibrosis and scarring in preclinical studies * Enleofen Bi...

2019-09-30 15:00 205

Kinoxis Therapeutics Awarded NIH HEAL Initiative Grant to Advance KNX100 for the Treatment of Opioid Withdrawal

MELBOURNE, Australia and SYDNEY, Sept. 29, 2019 /PRNewswire/ -- Kinoxis Therapeutics Pty Ltd, a pre-clinical stage biotechnology company developing novel therapies for substance use disorders and other central nervous system disorders, has been awarded a major grant from the US National Institut...

2019-09-30 05:00 284

Preclincal Results of Baoyuan's Next-Generation ROS1/NTRK Inhibitor AB-106 Published in Nature Communications

HANGZHOU, China, Sept. 25, 2019 /PRNewswire/ -- The preclinical results of AB-106 (original code: DS-6051b), an investigational next generation ROS1/NTRK dual inhibitor exclusively in-licensed by AnHeart Therapeutics, a wholly-owned subsidiary of Baoyuan Biopharmaceuticals Technology (Hangzhou) C...

2019-09-25 18:44 717

Preclincal Results of Baoyuan's Next-Generation ROS1/NTRK Inhibitor AB-106 Published in Nature Communications

HANGZHOU, China, Sept. 25, 2019 /PRNewswire/ -- The preclinical results of AB-106 (original code: DS-6051b), an investigational next generation ROS1/NTRK dual inhibitor exclusively in-licensed by AnHeart Therapeutics, a wholly-owned subsidiary of Baoyuan Biopharmaceuticals Technology (Hangzhou) C...

2019-09-25 18:35 737

AGC Biologics Appoints New Site Head/General Manager of Chiba, Japan Operations

Naofumi Kagami Named Site Head/General Manager  BOTHELL, Washington, Sept. 25, 2019 /PRNewswire/ -- AGC Biologics, a global leader in clinical and commercial manufacturing of therapeutic proteins, announced today the appointment ofNaofumi Kagami as Site Head/General Manager of theChiba, Japan fa...

2019-09-25 01:42 1059
12345 ... 145